Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1.

Yulia Vugmeyster,Justin Wilkins,Eleanor Harrison‐Moench,Wanping Geng,Andre Koenig,Liang Cao,James L. Gulley,Isabelle Dussault,Akash Khandelwal

Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1.

2018

Yulia Vugmeyster
Justin Wilkins
Eleanor Harrison‐Moench
Wanping Geng
Andre Koenig
Liang Cao
James L. Gulley
Isabelle Dussault
Akash Khandelwal

2566Background: The transforming growth factor β (TGF-β) pathway plays an important role in tumor immune escape and may enhance the response to PD-L1 monoclonal antibodies (mAb). M7824 is an innova...

Keywords:

Bifunctional
MSB0011359C
PD-L1
Fusion protein
Transforming growth factor
Cancer research
Pathology
Medicine
Tumor Immune Escape
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations